Tìm theo
Bisoprolol
Các tên gọi khác (4 ) :
  • (+-)-1-((alpha-(2-Isopropoxyethoxy)-P-tolyl)oxy)-3-(isopropylamino)-2-propanol
  • (RS)-1-(4-(2-isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol
  • Bisoprolol
  • Bisoprololum
Thuốc tim mạch
Thuốc Gốc
Small Molecule
CAS: 66722-44-9
ATC: C07AB07
ĐG : Atlantic Biologicals Corporation , http://www.atlanticbiologicals.com
CTHH: C18H31NO4
PTK: 325.443
Bisoprolol is a cardioselective β1-adrenergic blocking agent used for secondary prevention of myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. Bisoprolol is structurally similar to metoprolol, acebutolol and atenolol in that it has two substituents in the para position of the benzene ring. The β1-selectivity of these agents is thought to be due in part to the large substituents in the para position. At lower doses (less than 20 mg daily), bisoprolol selectively blocks cardiac β1-adrenergic receptors with little activity against β2-adrenergic receptors of the lungs and vascular smooth muscle. Receptor selectivity decreases with daily doses of 20 mg or greater. Unlike propranolol and pindolol, bisoprolol does not exhibit membrane-stabilizing or sympathomimetic activity. Bisoprolol possesses a single chiral centre and is administered as a racemic mixture. Only l-bisoprolol exhibits significant β-blocking activity.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C18H31NO4
Phân tử khối
325.443
Monoisotopic mass
325.225308485
InChI
InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3
InChI Key
InChIKey=VHYCDWMUTMEGQY-UHFFFAOYSA-N
IUPAC Name
[2-hydroxy-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propyl](propan-2-yl)amine
Traditional IUPAC Name
bisoprolol
SMILES
CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
Độ tan chảy
100 °C
Độ hòa tan
2240 mg/L
logP
1.87
logS
-3.7
pKa (strongest acidic)
14.09
pKa (Strongest Basic)
9.67
PSA
59.95 Å2
Refractivity
92.15 m3·mol-1
Polarizability
38.5 Å3
Rotatable Bond Count
12
H Bond Acceptor Count
5
H Bond Donor Count
2
Physiological Charge
1
Number of Rings
1
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Bisoprolol is a competitive, cardioselective β1-adrenergic antagonist. Activation of β1-receptors (located mainly in the heart) by epinephrine increases heart rate and the blood pressure causing the heart to consume more oxygen. β1-adrenergic blocking agents such as bisopolol lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. They are routinely prescribed in patients with ischemic heart disease. In addition, β1-selective blockers prevent the release of renin, a hormone produced by the kidneys causes constriction of blood vessels. Bisoprolol is lipophilic and exhibits no intrinsic sympathomimetic activity (ISA) or membrane-stabilizing activity.
Cơ Chế Tác Dụng : Bisoprolol is a cardioselective β1-adrenergic blocking agent used for secondary prevention of myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. Bisoprolol is structurally similar to metoprolol, acebutolol and atenolol in that it has two substituents in the para position of the benzene ring. The β1-selectivity of these agents is thought to be due in part to the large substituents in the para position. At lower doses (less than 20 mg daily), bisoprolol selectively blocks cardiac β1-adrenergic receptors with little activity against β2-adrenergic receptors of the lungs and vascular smooth muscle. Receptor selectivity decreases with daily doses of 20 mg or greater. Unlike propranolol and pindolol, bisoprolol does not exhibit membrane-stabilizing or sympathomimetic activity. Bisoprolol possesses a single chiral centre and is administered as a racemic mixture. Only l-bisoprolol exhibits significant β-blocking activity. Bisoprolol selectively blocks catecholamine stimulation of β1-adrenergic receptors in the heart and vascular smooth muscle. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. At higher doses (e.g. 20 mg and greater) bisoprolol may competitively block β2-adrenergic receptors in bronchial and vascular smooth muscle causing bronchospasm and vasodilation.
Dược Động Học :
▧ Absorption :
Well absorbed. Bioavailability > 80%. Absorption is not affected by food. Peak plasma concentrations occur within 2-4 hours.
▧ Protein binding :
Binding to serum proteins is approximately 30%
▧ Metabolism :
Approximately 50% of the dose is metabolized primarily metabolized by CYP3A4 to inactive metabolites. In vitro studies have shown that bisoprolol is also metabolized by CYP2D6 though this does not appear to be clinically significant. Approximately half the administered dose is excreted in unchanged in urine.
▧ Route of Elimination :
Eliminated equally by renal and non-renal pathways. Approximately 50% of the total orally administered dose is excreted unchanged in urine with the remainder appearing as inactive metabolites. Less than 2% of the dose is excreted in the feces.
▧ Half Life :
9-12 hours; prolonged in the elderly and those with decreased renal function
Độc Tính : Oral, mouse: LD50 = 100 mg/kg; Skin, rabbit: LD50 = 200 mg/kg; Skin, rat: LD50 = 500 mg/kg. Symptoms of overdose include congestive heart failure (marked by sudden weight gain, swelling of the legs, feet, and ankles, fatigue, and shortness of breath), difficult or labored breathing, low blood pressure, low blood sugar, and slow heartbeat.
Chỉ Định : For management of heart failure, angina pectoris, and mild to moderate hypertension and for secondary prevention of myocardial infarction (MI).
Tương Tác Thuốc :
  • Acetohexamide The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Chlorpropamide The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Clonidine Increased hypertension when clonidine stopped
  • Dihydroergotamine Ischemia with risk of gangrene
  • Disopyramide The beta-blocker, bisoprolol, may increase the toxicity of disopyramide.
  • Epinephrine Hypertension, then bradycardia
  • Ergonovine Ischemia with risk of gangrene
  • Ergotamine Ischemia with risk of gangrene
  • Fenoterol Antagonism
  • Formoterol Antagonism
  • Gliclazide The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Glipizide The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Glisoxepide The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Glyburide The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Glycodiazine The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Ibuprofen Risk of inhibition of renal prostaglandins
  • Indacaterol Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD.
  • Indomethacin Risk of inhibition of renal prostaglandins
  • Insulin Aspart The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Insulin Detemir The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Insulin Glargine The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Insulin Glulisine The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Insulin Lispro The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Isoprenaline Antagonism
  • Lidocaine The beta-blocker, bisoprolol, may increase the effect and toxicity of lidocaine.
  • Methysergide Ischemia with risk of gangrene
  • Orciprenaline Antagonism
  • Pipobroman Antagonism
  • Pirbuterol Antagonism
  • Piroxicam Risk of inhibition of renal prostaglandins
  • Prazosin Risk of hypotension at the beginning of therapy
  • Procaterol Antagonism
  • Repaglinide The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Rifampicin Rifampin may decrease the serum concentration of bisprolol by increasing its metabolism.
  • Salbutamol Antagonism
  • Salmeterol Antagonism
  • Telithromycin Telithromycin may reduce clearance of Bisoprolol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bisoprolol if Telithromycin is initiated, discontinued or dose changed.
  • Terazosin Increased risk of hypotension. Initiate concomitant therapy cautiously.
  • Terbutaline Antagonism
  • Tolazamide The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Tolbutamide The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
  • Treprostinil Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
  • Verapamil Increased effect of both drugs
  • Voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bisoprolol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bisoprolol if voriconazole is initiated, discontinued or dose changed.
Liều Lượng & Cách Dùng : Tablet, film coated - Oral - 10 mg
Tablet, film coated - Oral - 5 mg
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : Bayer
    Sản phẩm biệt dược : Cardicor
  • Công ty : Merck
    Sản phẩm biệt dược : Concor
  • Công ty : Merck
    Sản phẩm biệt dược : Concore
  • Công ty : Merck Santé
    Sản phẩm biệt dược : Detensiel
  • Công ty : Merck
    Sản phẩm biệt dược : Emconcor
  • Công ty : Merck
    Sản phẩm biệt dược : Emcor
  • Công ty : Lacer
    Sản phẩm biệt dược : Euradal
  • Công ty : Meda
    Sản phẩm biệt dược : Isoten
  • Sản phẩm biệt dược : Monocor
  • Công ty : Helsinn
    Sản phẩm biệt dược : Soprol
  • Công ty : Barr
    Sản phẩm biệt dược : Zebeta
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00612
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=2405
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508844
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C06852
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D02342
ChemSpider
http://www.chemspider.com/Chemical-Structure.2312.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=25751
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0378-0523-93
PharmGKB
http://www.pharmgkb.org/drug/PA448641
Wikipedia
http://en.wikipedia.org/wiki/Bisoprolol
RxList
http://www.rxlist.com/cgi/generic3/bisoprolol.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/zeb1667.shtml
Drugs.com
http://www.drugs.com/bisoprolol.html
... loading
... loading